// App-Quantinova.ai

678 : A phase 2 study of evorpacept (ALX148) in combination with pembrolizumab in patients with advanced head and neck squamous cell carcinoma (HNSCC); ASPEN-03

Researchers

Presenter

  • Kevin Harrington

Principal Investigators

  • Ezra Cohen

  • Bhumsuk Keam

  • Jean-Pascal Machiels

  • Sjoukje Oosting

  • Brett Hughes

  • Jong Chul Park

  • Tim Welliver

  • Christine Ju

  • Feng Jin

  • Alison Forgie

  • Jaume Pons

  • Sophia Randolph

  • Athanasios Tsiatis

Medical Centers

  • Seoul National University Hospital, Seoul, Korea

  • Massachusetts General Hospital Cancer Center, Boston, MA

  • Royal Brisbane and Women's Hospital, Herston, Australia

  • University of California, San Diego, La Jolla, CA

  • University Medical Center Groningen, Nijmegen, Netherlands

  • Royal Marsden Hospital, Sutton, UK

  • Cliniques Universitaires Saint-Luc, UCL, Brussels, MN, Belgium

Locations

  • Republic of South Korea

  • Australia

  • United States

  • United Kingdom

  • Netherlands

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Squamous cell carcinoma of the head and neck

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

  • ALX148

Outcome

  • N/A

Study Design

  • Randomized

  • Pharmacodynamics

  • Open Label

  • Non-Comparative

  • Cohort

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved